A5006776440- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Urinary Bladder and Prostate Research
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Pelvic floor disorders treatments
- Urologic and reproductive health conditions
- Esophageal Cancer Research and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Urological Disorders and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Gut microbiota and health
- Multiple and Secondary Primary Cancers
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Surgical Treatments
- Lung Cancer Research Studies
- Minimally Invasive Surgical Techniques
- Morinda citrifolia extract uses
- Synthesis and Biological Activity
- Economic and Financial Impacts of Cancer
- Kidney Stones and Urolithiasis Treatments
- Neutropenia and Cancer Infections
Tokyo Medical University
2014-2025
Tokyo Medical University Hospital
2024
Cedars-Sinai Medical Center
2020-2021
Keio University
2014
Saitama Municipal Hospital
2012-2013
Abstract Objectives Enfortumab vedotin (EV) is a novel antibody–drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in efficacy of EV after each ICIs and prognostic factors are not well known. We aimed compare patients UC who were treated avelumab or pembrolizumab identify factors. Methods The records 100 advanced received administration either retrospectively collected from five...
Objectives To explore the characteristics of patients and assess effectiveness enfortumab vedotin (EV) in those with treatment‐resistant advanced urothelial cancer a real‐world setting. Patients Methods A multicenter observational study was conducted on 103 evaluable who received EV. Outcomes were assessed by radiographic response, progression‐free survival (PFS), overall (OS), treatment‐related adverse events (trAEs). Radiographic response using Response Evaluation Criteria Solid Tumors...
Due to insufficient accuracy, urine-based assays currently have a limited role in the management of patients with bladder cancer. The identification multiplex molecular signatures associated disease has potential address this deficiency and assist accurate, non-invasive diagnosis monitoring.To evaluate performance Oncuria™, immunoassay for detection voided urine samples. test was evaluated multi-institutional cohort 362 prospectively collected subjects presenting cancer evaluation. parallel...
Combining an immune checkpoint inhibitor with a tumor vaccine may modulate the system to leverage complementary mechanisms of action that lead sustained T-cell activation and potent prolonged immunotherapeutic response in metastatic castration resistant prostate cancer (mCRPC).Subjects asymptomatic or minimally symptomatic mCRPC were randomly assigned 1:1 ratio receive either atezolizumab followed by sipuleucel-T (Arm 1) 2). The primary endpoint was safety, while secondary endpoints included...
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does study add? Transurethral enucleation with bipolar (TUEB) has been widely adopted as an alternative to standard TURP, although surgical technique, efficacy safety TUEB have not described so far. The present provides illustrations well peri‐operative, 6‐month 12‐month follow‐up results from a retrospective review single‐institution experience comparing transurethral resection in saline for...
To investigate perioperative outcomes, the learning curve, and 2-year follow-up after transurethral enucleation with bipolar (TUEB) for patients benign prostatic hyperplasia (BPH).From December 2011 to October 2016, 603 consecutive underwent TUEB BPH, performed by a single surgeon. Patients were preoperatively assessed using International Prostate Symptom Score (IPSS), quality-of-life score (QOLs), serum prostate-specific antigen (PSA), uroflowmetry evaluation. Intra- post-operative outcomes...
To investigate the predictive factors for transient urinary incontinence after transurethral enucleation with bipolar.We retrospectively analyzed data of 584 patients who underwent bipolar between December 2011 and September 2016 operated by a single surgeon. Urinary was defined as involuntary leakage urine that required use pads. It evaluated at 1 week, 1, 3, 6, 12 24 months bipolar. We persisting up to month Based on independent risk identified multivariate stepwise logistic regression...
Serum C-reactive protein (CRP) is known to be a biomarker for systemic inflammatory reactions. In the present study, we sought measure predictive value of serum CRP level metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab and nivolumab using our real-world clinical dataset including non-clear RCC (nccRCC). The record patients who underwent plus treatment mRCC ccRCC nccRCC from 2018 2021 was retrospectively analyzed. All were diagnosed either intermediate or poor-risk...
Urinary incontinence is one of the most bothersome adversities after robot-assisted radical prostatectomy (RARP). The aim this study was to investigate urinary continence recovery and effect various surgical techniques.We previously reported that posterior rhabdosphincter reconstruction nerve-sparing were independent predictors 1 month catheter removal in 199 patients who underwent RARP. Retrospectively, we further reviewed those for at 3 months or later relationships with perioperative...
The endocrine therapy is effective for patients with advanced prostate cancer, but the disease eventually becomes refractory to treatment. aim of this study was investigate prognostic factors and develop a risk stratification model survival in cancer undergoing therapy.This included 197 stage IV who were treated as primary treatment at Tokyo Medical University, Tokyo, Japan, between January 1999 November 2012. Prognostic values including baseline clinical laboratory before examined. Patients...
<b><i>Introduction:</i></b> We aimed to perform a multi-institutional study using national database led by the Japanese Society of Endourology investigate effect surgeon or hospital volume on safety robot-assisted radical prostatectomy (RARP). <b><i>Materials and Methods:</i></b> Clinical data 3,214 patients who underwent RARP for treatment clinically localized prostate cancer between April 2012 March 2013 in Japan were evaluated. Surgical...
Few studies have evaluated the usefulness of anteroposterior dissection holmium laser enucleation prostate (HoLEP). Thus, this study investigated incidence stress urinary incontinence (SUI) after HoLEP and in preventing postoperative SUI.
Abstract Objectives Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in efficacy of EV after each ICIs and prognostic factors are not well known. We aimed compare patients UC who were treated avelumab or pembrolizumab identify factors. Methods The records 100 advanced received administration either retrospectively collected from five...
e17564 Background: Combining an immune checkpoint inhibitor with a tumor vaccine may leverage complementary mechanisms of action for treatment mCRPC. Atezolizumab, fully human anti–PD-L1 IgG1 antibody, is approved option in multiple indications; while SipT, autologous cellular immunotherapeutic, metastatic castrate resistant prostate cancer (mCRPC). We present phase Ib study evaluating safety, tolerability and objective response rate atezolizumab + SipT patients mCRPC (NCT03024216). Methods:...
Pembrolizumab has now become a standard of care in metastatic urothelial carcinoma (mUC), although the treatment effect drug substantially differs among individuals. Emerging evidence suggests that radiotherapy exerts synergistic with PD-1 blockade. We sought to elucidate survival outcomes patients who underwent palliative radiation pembrolizumab treatment.We retrospectively investigated our multi-institutional dataset 235 platinum-refractory mUC treated as second-line treatment, collected...
There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non-metastatic castration-resistant prostate cancer (nmCRPC). In this study, we conducted a comparative analysis real-world survival outcomes between AA and enzalutamide (Enz) in nmCRPC, utilizing our consortium dataset.The clinical records 133 nmCRPC treated first-line Enz or were analyzed. The primary endpoints the study overall (OS) cancer-specific (CSS). Cumulative incidence function (CIF) using Fine...